| Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. Co.'s primary product candidates include: CYAD-101, which is an investigational, non-gene edited, allogeneic CAR T candidate engineered to co-express a CAR based on natural killer group 2D ligands, a receptor expressed on natural killer cells that binds to eight stress-induced ligands and T cell receptor inhibitory molecule; and CYAD-211, which is an investigational, short hairpin RNA-based allogeneic CAR T candidate for the treatment of relapsed / refractory multiple myeloma. We show 1 historical shares outstanding datapoints in our CYAD shares outstanding history coverage, used to compute CYAD market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CYAD market cap history over the course of time is important for investors
interested in comparing CYAD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CYAD versus a peer is one thing; comparing
CYAD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CYAD can fluctuate over the course of history.
With this page we aim to empower investors researching CYAD by allowing them to research the CYAD market cap history.